Recent progress of JAK inhibitors for hematological disorders

Recent progress of JAK inhibitors for hematological disorders

AbstractJAK inhibitors are important therapeutic options for hematological disorders, especially myeloproliferative neoplasms. Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both myelofibrosis and polycythemia vera pat...

Full description

Bibliographic Details
Main Author: Keita Kirito
Format: Article
Language:English
Published: Taylor & Francis Group 2023-07-01
Series:Immunological Medicine
Subjects:
JAK inhibitor
myeloproliferative neoplasms
myelofibrosis
ruxolitinib
GVHD
Online Access:https://www.tandfonline.com/doi/10.1080/25785826.2022.2139317

Internet

https://www.tandfonline.com/doi/10.1080/25785826.2022.2139317

Similar Items